In 2007, the agency approved Lialda, generically known as mesalamine, for induction of remission in patients with active, mild to moderate ulcerative colitis.
Read the Shire Pharmaceuticals release on Lialda.
Read the FDA statement about Lialda.
Related Articles on FDA Approvals:
FDA Approves Lazanda Nasal Spray for Cancer Pain
FDA Clears New Version of PillCam for Esophageal Mucosa
St. Jude Gets FDA Approval for Epiducer Neurostimulation Delivery System
